The PRPP synthetase spectrum: what does it demonstrate about nucleotide syndromes?

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• X-linked phosphoribosylpyrophosphate synthetase 1 (PRPS1) gene defects lead to diverse clinical manifestations.
• These disorders are linked to altered nucleotide synthesis and regulation, impacting purine and pyrimidine metabolism.

Purpose of the Study:

• To elucidate the spectrum of PRPS1-related disorders and their underlying molecular mechanisms.
• To differentiate nucleotide depletion from nucleotide toxicity disorders.
• To explore potential therapeutic avenues, such as S-adenosylmethionine (SAMe).

Main Methods:

• Analysis of PRPS1 mutations and their correlation with enzyme activity (superactivity, deficiency).
• Review of nucleotide metabolism pathways, including phosphoribosyl-pyrophosphate (PRPP) dependence.
• Comparison of clinical outcomes in nucleotide depletion versus toxicity disorders.

Main Results:

• PRPS1 defects result in PRS-I enzyme superactivity or deficiency, leading to nucleotide depletion.
• Disorders include Arts syndrome, Charcot-Marie-Tooth disease-5, and Deafness-2.
• S-adenosylmethionine (SAMe) shows potential in alleviating purine depletion via a PRPP-independent pathway.
• Nucleotide toxicity disorders, unlike depletion, involve abnormal nucleotide accumulation and are not improved by SAMe.

Conclusions:

• PRPS1 disorders represent a spectrum of nucleotide depletion conditions.
• Understanding the distinction between nucleotide depletion and toxicity is crucial for diagnosis and treatment.
• SAMe therapy warrants further investigation for PRPS1-related purine depletion and potentially mitochondrial disorders.